

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Canadian Cancer Trials Group | Cooperative Trials Group for Neuro-Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Details : Vorasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Astrocytoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Canadian Cancer Trials Group | Cooperative Trials Group for Neuro-Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vorasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves NGS Diagnostic for Grade 2 IDH-Mutant Glioma Therapy
Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma in 12 year and above patients.
Product Name : Voranigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Servier’s VORANIGO® Receives FDA Approval as First Targeted Therapy for IDH Glioma
Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $905.0 million
Deal Type : Agreement
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Details : Royalty Pharma gain rights for AG-881 (vorasidenib), an oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1/2 enzymes for the treatment of IDH-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $905.0 million
August 06, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $905.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Royalty Pharma
Deal Size : $905.0 million
Deal Type : Agreement
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
Details : Royalty Pharma gain rights for AG-881 (vorasidenib), an oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1/2 enzymes for the treatment of IDH-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $905.0 million
May 28, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Royalty Pharma
Deal Size : $905.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA and EMA Accept Vorasidenib Submissions for IDH-Mutant Glioma
Details : AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for IDH-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vorasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
